Rebyota™ (fecal microbiota, live - jslm) – New orphan drug approval
November 30, 2022 - The FDA announced the approval of Ferring Pharmaceuticals’ Rebyota (fecal microbiota, live - jslm), for the prevention of recurrence of Clostridioides difficile (C. difficile) infection (CDI) in individuals 18 years of age and older following antibiotic treatment for recurrent CDI.
Top